Jim Cramer's Mad Dash: Is Bristol-Myers in Trouble?

NEW YORK (TheStreet) -- Bristol-Myers Squibb  (BMY) was downgraded by BMO to hold from buy. On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said the downgrade actually has merit. 

Regarding the rating change, he called it "a downgrade that is going to send quivers through people."

The downgrade matters because it specifically questions the company's cancer applications pipeline, Cramer said, adding that Bristol-Myers is highly valued compared to its peers. 

Cramer admitted to liking shares of Bristol-Myers, but suggested that investors read the downgrade report -- as will he, for the second time. 

Turning to Plug Power (PLUG), the stock was upgraded by Cowen & Company to buy from hold. The analyst cited busy factory activity as the catalyst for its upgrade. 

The stock just did a "gigantic" secondary offering, Cramer said, and reiterated that he is not a buyer of the stock.

-- Written by Bret Kenwell in Petoskey, Mich.

>>Read More: Cisco Surges on Earnings Beat, Eyes Growth

>>Read More: It's Not Too Late to Detach From Plug Power

>>Read More: 5 Lowest-Priced 2014 Cars You'll Actually Want to Drive

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact